Analysis of treatment results and survival rates with assessment of prognostic factors in locally advanced well-differentiated thyroid cancer
https://doi.org/10.33667/2078-5631-2022-13-14-17
Abstract
Objective. To analyze the results of treatment and prognostic factors of general and relapse-free survival in patients with locally advanced welldifferentiated thyroid cancer who received surgical treatment, radiation therapy, radioiodine therapy and chemotherapy.
Methods. The retrospective study included patients with a verified diagnosis of locally advanced well-differentiated thyroid cancer who received treatment at the National Medical Research Centre of Oncology n. a. N. N. Petrov (Saint Petersburg, Russia). The study endpoints were overall and disease-free survival.
Results. Seventy-six patients were included in the study. The average age of patients was 60.0 (20.3) years, the median age was 62.0 (52.8–73.0) years. 25 (32.9 %) of 76 patients were male. The median overall survival was 109.0 months, and the 5-year overall survival rate was 80 months (95 % CI: 65.6–97.5). The median relapse-free survival was 108.6 months (the lower limit was 95 % CI was 56.7), and the 5-year relapse-free survival rate was 62.1 months (95 % CI: 46.5–83.0).
Conclusion. Analysis of risk factors revealed a statistically significant relationship between tumor invasion into the larynx and chemotherapy. Factors such as the patient’s age and neck lymph node surgery are associated with the risk of recurrence or death.
About the Authors
Z. A.-G. Radzhabova
National Medical Research Centre of Oncology n. a. N. N. Petrov
Russian Federation
Russian Federation
Radzhabova Zamira A.-G., PhD Med, associate professor, head of Dept of Headand Neck Tumors
Saint Petersburg
M. A. Kotov
National Medical Research Centre of Oncology n. a. N. N. Petrov
Russian Federation
Russian Federation
Kotov Maxim A., PhD Med, oncologist at Dept of Head and Neck Tumors
Saint Petersburg
A. S. Mitrofanov
National Medical Research Centre of Oncology n. a. N. N. Petrov
Russian Federation
Russian Federation
Mitrofanov Aleksandr S., oncologist at Dept of Head and Neck Tumors
Saint Petersburg
M. A. Radzhabova
National Medical Research Centre of Oncology n. a. N. N. Petrov
Russian Federation
Russian Federation
Radzhabova Madina A., oncologist at Dept of Head and Neck Tumors
Saint Petersburg
References
1. Shaha A.R. Controversies in the management of thyroid nodule. Laryngoscope 2000; 110.
2. Cody H.S. 3rd, Shah J.P. Locally invasive, well-differentiated thyroid cancer: 22 years; experience at Memorial Sloan-Kettering Cancer Center. Am J Surg 1981; 42: 480–483.
3. Andersen P.E., Kinsella J.., Loree TR., et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170: 467–470.
4. Falvo L., Catania A., Grilli P., et al. Treatment of ‘locally advanced’ well-differentiated thyroid carcinomas. Ann Ital Chir 2004; 75: 17–21.
5. Schlumberger M., Tahara M., Wirth L.J., Robinson B., Brose M.S., Elisei R., et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372 (7): 621e30.
6. Wells Jr S. A., Robinson BG., Gagel R. F., Dralle H., Fagin J. A., Santoro M., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol 2012; 30 (2): 134e41.
7. Subbiah V., Kreitman R.J.., Wainberg ZA., Cho J.Y., Schellens J.H.M., Soria J.C., et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol: official journal of the American Society of Clinical Oncology 2018; 36 (1): 7e13.
8. Iyer P.C., Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S., Lavis V.R., et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid: official journal of the American Thyroid Association 2018; 28 (10): 1243e51.
9. Cabanillas M.E., Ferrarotto R., Garden A.S., Ahmed S., Busaidy N.L., Dadu R., et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid: official journal of the American Thyroid Association. 2018; 28 (7): 945e51.
10. Iyer P.C., Dadu R., Ferrarotto R., Busaidy N.L., Habra M.A., Zafereo M., et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid: official journal of the American Thyroid Association 2018; 28 (1): 79e87.
11. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
12. Nixon I.J., Ganly I., Patel S., Palmer F.L., Whitcher M.M., Tuttle R.M., et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 2011; 150: 1242–9.
13. Wang L.Y., Nixon I.J., Patel S.G., Palmer F.L., Tuttle R.M., Shaha A., Shah J.P., Ganly I. Operative management of locally advanced, differentiated thyroid cancer. Surgery. 2016 Sep; 160 (3): 738–46.
14. Shin D.H., Mark E.J., Suen H.C., Grillo H.C. Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: A clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection. Hum Pathol 1993; 24: 866–70.
15. Gaissert H.A., Honings J., Grillo H.C., Donahue D.M., Wain J.C., Wright C.D., et al. Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann Thorac Surg 2007; 83: 1952–9.
16. Breaux G.P. Jr, Guillamondegui O.M. Treatment of locally invasive carcinoma of the thyroid: How radical? Am J Surg 1980; 140: 514–7.
17. Rosa Pelizzo M., Toniato A., Boschin I.M., Piotto A., Bernante P., Pagetta C., et al. Locally advanced differentiated thyroid carcinoma: A 35-year mono-institutional experience in 280 patients. Nucl Med Commun 2005; 26: 965–8.
18. Friedman M., Danielzadeh J.A., Caldarelli D.D. Treatment of patients with carcinoma of the thyroid invading the airway. Arch Otolaryngol Head Neck Surg 1994; 120: 1377–81.
19. McCaffrey J.C. Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma. Cancer Control 2000; 7: 246–52.
20. Wada N., Nakayama H., Masudo Y., Suganuma N., Rio Y. Clinical outcome of different modes of resection in papillary thyroid carcinomas with laryngotracheal invasion. Langenbecks Arch Surg 2006; 391: 545–9.
21. Nishida T., Nakao K., Hamaji M. Differentiated thyroid carcinoma with airway invasion: Indication for tracheal resection based on the extent of cancer invasion. J Thorac Cardiovasc Surg 1997; 114: 84–92.
22. Segal K., Shpitzer T., Hazan A., Bachar G., Marshak G., Popovtzer A. Invasive well-differentiated thyroid carcinoma: Effect of treatment modalities on outcome. Otolaryngol Head Neck Surg 2006; 134: 819–22.
23. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1–133.
Review
For citations:
Radzhabova Z.A., Kotov M.A., Mitrofanov A.S., Radzhabova M.A. Analysis of treatment results and survival rates with assessment of prognostic factors in locally advanced well-differentiated thyroid cancer. Medical alphabet. 2022;(13):14-17. (In Russ.) https://doi.org/10.33667/2078-5631-2022-13-14-17
Views:
291
Email this article 